Loading Events
Find Events

Event Views Navigation

Upcoming Events

Events List Navigation

April 2018

Cycle 3: NIH Small Business Grants

April 5

DUE DATE: APRIL 5, 2018

Small Business Innovation Research (SBIR): These programs congressionally require eligible governmental agencies to set aside a percentage of their extramural budget so that domestic small businesses can engage in R&D that has a strong potential for technology commercialization. Total costs for Phase I and Phase II usually do not exceed $1,150,000; no funding is provided for Phase III.

Small Business Technology Transfer (STTR): These programs congressionally require eligible governmental agencies to set aside a percentage of their extramural budget so that domestic small businesses can engage in R&D that has a strong potential for technology commercialization. Total costs for Phase I and Phase II usually do not exceed $1,150,000; no funding is provided for Phase III.

Find out more »

Cycle 3: NIH R41, R42, R43, R44, U43, U44

April 5

DUE DATE: APRIL 5, 2018

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Innovation Research (SBIR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

20th International Neuroscience Winter Conference

April 11 - April 15

This conference has been established as a high-quality meeting on contemporary neuroscience for many years. For the 20th conference we aim at topping previous programs by inviting most distinguished neuroscientists as keynote speakers and select high-quality symposia. Abstract deadline February 23, 2018.

Find out more »

Stem Cell Summit 2018

April 12 - April 13
Hyatt Regency Boston, 1 Ave De Lafayette
Boston, MA 02111 United States

GTCbio is proud to present the Stem Cell Summit 2018, to be held in Boston, MA. The Stem Cell Summit provides information on cutting-edge developments in all areas of stem cell research from bench to bedside, including the biology, medicine, applications, regulations, product development, and the commercialization of stem cells. This summit comprises of presentations, panels and round-table discussions to highlight pre-clinical and clinical studies in regenerative medicine, immunotherapy, stem cell reprogramming, cell therapy in diabetes, regulatory policies regarding stem cell research, manufacturing and other relevant topics.

Find out more »

American Academy of Neurology Annual Meeting 2018

April 21 - April 27
Los Angeles Convention Center, 1201 S. Figueroa Street
Los Angeles, CA 90015 United States

The AAN Annual Meeting is the world’s largest gathering of neurologists, bringing together more than 10,000 neurology professionals across the globe to network, discuss cutting-edge research, and take part in top-rated education programming across a wide variety of topics.

Find out more »

PEGS – The Essential Protein Engineering Summit

April 30 - May 4

PEGS: The Essential Protein Engineering Summit is one of the industry’s most preeminent events that inspires accelerated biotherapeutic protein drug development. This weeklong event attracts over 2,300 international participants, and features nearly 400 presentations by world renowned leaders from pharma, academia, and government showcasing case studies, cutting edge data, insight and perspective. Conference programs include a broad spectrum of topics including protein and antibody engineering, cancer immunotherapy, oncology, and emerging therapeutics.

Find out more »
May 2018

Traumatic Brain Injury Conference 2018

May 16 - May 17

Arrowhead Publishers is pleased to announce its 8th Annual Traumatic Brain Injury Conference is coming back to Washington, DC on May 16-17, 2018. This conference brings together researchers and clinicians from industry, academia, the military and government to present ground-breaking research in a variety of areas related to traumatic brain injury. This event provides a special opportunity for a variety of stakeholders to present original research and analysis aimed at providing a full picture of the progress being made towards better diagnosis, treatment and long-term care for TBI survivors. At this annual event, physicians, nurses, neurosurgeons, scientists, and drug/diagnostic developers from all over the world network and learn from one another.

Find out more »
June 2018

American Association of Neuropathologists Annual Meeting 2018

June 7 - June 10

The AANP is proud to be the only association exclusively focused on the clinical and scientific practice of neuropathology in the United States. During the first week of every June, AANP provides cutting-edge educational sessions led by the nation’s preeminent neuropathologists at their Annual Meeting. The meeting includes a one-day Special Course, which features two “What Every Neuropathologist Needs to Know” sessions, two days of scientific sessions (platform and poster), an evening Diagnostic Slide Session, and a half-day Presidential Symposium.

Find out more »
July 2018

Cycle 7: NINDS CREATE Bio Discovery Track: Optimization in Preparation for Development of Biotechnology Products and Biologics (U01)

July 18

Sponsor: National Institute of Neurological Disorders and Stroke
Due Date: July 18, 2017
Award: Actual needs; Budgets for these projects will normally remain under $500,000 in direct costs in any given year and fluctuate over the funding period based on the stage of the project.

Find out more »
September 2018

Cycle 1: NIH Small Business Grants

September 5

DUE DATE: SEPTEMBER 5, 2018

Small Business Innovation Research (SBIR): These programs congressionally require eligible governmental agencies to set aside a percentage of their extramural budget so that domestic small businesses can engage in R&D that has a strong potential for technology commercialization. Total costs for Phase I and Phase II usually do not exceed $1,150,000; no funding is provided for Phase III.

Small Business Technology Transfer (STTR): These programs congressionally require eligible governmental agencies to set aside a percentage of their extramural budget so that domestic small businesses can engage in R&D that has a strong potential for technology commercialization. Total costs for Phase I and Phase II usually do not exceed $1,150,000; no funding is provided for Phase III.

Find out more »

Cycle 1: NIH R41, R42, R43, R44, U43, U44

September 5

 

DUE DATE: SEPTEMBER 5, 2018

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Innovation Research (SBIR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »
January 2019

ANGEL (Advanced Neurotherapeutic Grant of Excellence) Award

January 1, 2019

Sponsor: International Rett Syndrome Foundation (IRSF)
Due Date: Applications accepted on a rolling basis
Award: Up to $600,000 over two years

Find out more »

The Biomarkers Consortium

January 1, 2019

Sponsor: Foundation for the National Institutes of Health
Due Date: Rolling basis
Award: If a project idea is approved for further development and implementation, the Foundation for the National Institutes of Health will seek funding to support the resulting project and manage its execution.

Find out more »

Cycle 2: NIH Small Business Grant

January 5, 2019

DUE DATE: January 5, 2019

Small Business Innovation Research (SBIR): These programs congressionally require eligible governmental agencies to set aside a percentage of their extramural budget so that domestic small businesses can engage in R&D that has a strong potential for technology commercialization. Total costs for Phase I and Phase II usually do not exceed $1,150,000; no funding is provided for Phase III.

Small Business Technology Transfer (STTR): These programs congressionally require eligible governmental agencies to set aside a percentage of their extramural budget so that domestic small businesses can engage in R&D that has a strong potential for technology commercialization. Total costs for Phase I and Phase II usually do not exceed $1,150,000; no funding is provided for Phase III.

Find out more »

Cycle 2: NIH R41, R42, R43, R44, U43, U44

January 5, 2019

DUE DATE: JANUARY 5, 2019

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Innovation Research (SBIR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »
+ Export Events